---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-011024"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2024-03-22T23:59:59+00:00"
generated_at: "2026-06-04T09:07:08.507104+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# AgeX Therapeutics reports FY2023 net loss $14.8M; cash only $0.3M; going concern doubt

## Summary
- Net loss $14.8M in FY2023 vs $10.5M in FY2022; EPS ($13.73) vs ($9.70) (basic/diluted).
- Cash and equivalents $0.3M at Dec 31, 2023; $4.5M owed to Juvenescence under line of credit.
- Operating expenses rose to $10.1M from $7.0M, mainly due to merger due diligence and legal fees.
- AgeX expresses substantial doubt about going concern; cash insufficient for next 12 months.
- Stockholders approved merger with Serina Therapeutics; line of credit increased $4.4M, repayment extended to May 2024.

## SEC filing metadata
- accession: 0001493152-24-011024
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2024-03-22T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000149315224011024/0001493152-24-011024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000149315224011024/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-011024
- JSON: https://secwatch.observer/filing/0001493152-24-011024.json
- Plain text: https://secwatch.observer/filing/0001493152-24-011024.txt

## Key facts
- Earnings Releases
  Serina Therapeutics, Inc. reported financial results for fourth quarter and fiscal year ended December 31, 2023.
  - Period: fourth quarter and fiscal year ended December 31, 2023
  - Result: reported results
  source text: On March 22, 2024, AgeX issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000149315224011024/0001493152-24-011024-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.